Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year. At the time of writing, stock’s 50-day Moving Average stood at $7.10, while the 200-day Moving Average is $6.71.
VKTX has been the topic of several analyst reports. Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced... May 12, 2020.
Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Thursday, April 30th. [Operator instructions] As a reminder, this conference call is being recorded today, July 29, 2020. During the day,...Service Corporation International (NYSE: SCI) open the trading on July 30, 2020, with great promise as it jumped 5.42% to $43.40.
Finally, BTIG Research assumed coverage on Viking Therapeutics in a research report on Friday, May 1st. During the day, the stock rose to $7.18 and sunk to $6.62 before settling in for the price of $7.09 at the close. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 40.00% through the next 5 years, which can be compared against the 32.40% growth it accomplished over the previous five years trading on the market.
During the day, the...As on July 30, 2020, Stanley Black & Decker Inc. (NYSE: SWK) started slowly as it slid -1.04% to $154.46.
Maxim Group assumed coverage on Viking Therapeutics in a research report on Saturday, May 2nd.
According to the most recent insider trade that took place on Jun 30, this organization’s Director sold 13,000 shares at the rate of 7.35, making the entire transaction reach 95,550 in total value, affecting insider ownership by 26,250.
Taking a more long-term approach, VKTX posted a 52-week range of $3.26-$8.87. Meanwhile, its Annual Earning per share during the time was 32.40%. This publicly-traded company’s shares outstanding now amounts to $72.36 million, simultaneously with a float of $63.19 million.
Viking Therapeutics Inc (NASDAQ:VKTX) was the recipient of a large drop in short interest in the month of July. During the day, the...
Viking Therapeutics Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting. Stifel Nicolaus reissued a “buy” rating and set a $14.00 target price on shares of Viking Therapeutics in a research report on Thursday, April 30th. Meanwhile, its Annual Earning per share during the time was 32.40%. Witnessing the stock’s movement on the chart, on July 30, 2020, Catalent Inc. (NYSE: CTLT) set off with pace as it heaved 8.07% to...
During the day,...Witnessing the stock’s movement on the chart, on July 30, 2020, Cheniere Energy Inc. (AMEX: LNG) set off with pace as it heaved 0.16%...American Express Company (NYSE: AXP) flaunted slowness of -2.11% at $94.65, as the Stock market unbolted on July 30, 2020.
In the latest quarterly report released, which was put into the public domain on 3/30/2020, the organization reported -$0.13 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -$0.12) by -$0.01. Viking Therapeutics(NASDAQ:VKTX)Q22020 Earnings CallJul 29, 2020, 4:30 p.m. The organization now has a market capitalization sitting at $497.73 million.
Earnings results for Viking Therapeutics (NASDAQ:VKTX) Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on […]
During the day,...
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Welcome to the Viking Therapeutics 2020 second-quarter financial results conference call.
The transaction was disclosed in a document filed with the SEC, which can be accessed through Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. It’s Quick Ratio in the last reported quarter now stands at 32.40. The biotechnology company reported ($0.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.01). Nevertheless, stock’s Earnings Per Share (EPS) this year is 6.50%.
Viking Therapeutics (NASDAQ:VKTX) will issue its quarterly earnings data after the market closes on Wednesday, July 29th.
They issued a “buy” rating and a $9.00 price target on the stock.
If we take a close look at the recent performances of Viking Therapeutics Inc. (NASDAQ: VKTX), its last 5-days Average volume was 1.91 million that shows progress from its year to date volume of 1.51 million.